“Cocktail”探针药物法的研究进展

摘要/Abstract

摘要： "Cocktail"( 鸡尾酒) 探针药物法是一次给予两种或多种的探针药物的方法。本文主要介绍“Cocktail”探针药物法在测定药物代谢酶活性以评价药物间相互作用、研究药物代谢酶活性与疾病之间关系、研究遗传或非遗传因素对代谢酶活性影响的应用。简要介绍了“Cocktail” 探针药物法在临床研究中的应用, 并且对体内药物代谢酶活性测定的“Cocktail”探针等方面进行较全面的综述。

关键词: "鸡尾酒"探针药物法, 细胞色素P450, 应用

Abstract: The method of simultaneous administration of several probe substrates is called “Cocktail” approaches.The objective of the article is to review the application of this technique in characterizing the activity of multiple drug-metabolizing enzymes and in clinical researches.This paper also shows Five-drug and Six-drug Cocktail set for evaluating in vivo activity of drug-metabolizing enzymes.

Key words: Cocktail, cytochrome P450, application

中图分类号:

R969

刘颖, 焦建杰, 娄建石. “Cocktail”探针药物法的研究进展[J]. 中国临床药理学与治疗学, 2006, 11(11): 1225-1229.

LIU Ying, JIAO Jian-jie, LOU Jian-shi. Progress of “Cocktail” probe substrates approaches[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(11): 1225-1229.

参考文献

1 BreimerDD.Interindividual variations in drug disposition.Clinical implications and methods of investigation[J].Clin Pharmacokinet,1983;8:371-7
2 BreimerDD, Schellens JHM.A ' cocktail' strategy to assess in vivo oxidative drug metabolism in humans[J].Trends Pharmacol Sci, 1990;11:223-5
3 Schellens JHM, Ghabrial H, van derWart HHF, BakkerEN,Wilkinson GR, BreimerDD.Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans[J].Clin Pharmacol Ther, 1991;50:520-8
4 Shelepova T, NafzigerAN, Victory J, Kashuba AD, Rowland E,et alZhang Y..Effect of a triphasic oral contraceptive on drugmetabolizing enzyme activity as measured by the validated cooperstown 5 +1 cocktail[J].J Clin Pharmacol, 2005;45:1413-21
5 扈金萍, 闫淑莲, 唐静成, 张锦楠.Cocktail 探针药物评价姜黄对肝细胞色素P450 酶的影响[J].首都医科大学学报, 2004;25:427-30
6 闫淑莲, 扈金萍, 徐艳霞, 张锦楠.Cocktail 探针药物同时评价连翘对肝细胞色素P450 的影响[J].中国药学杂志,2003;38:761-63
7 Liu S, Frye RF, Branch RA, Venkataramanan R, Fung JJ, Burckart GJ.Effect of age and postoperative time on cytochrome p450 enzyme activity following livertransplantation[J].J Clin Pharmacol,2005;45:666-73
8 May CB, Csuka ME, Lupoli S,Wilkinson GR, Branch RA.Activity of oxidative routes of metabolism of debrisoquin, mephenytoin,and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease[J].Clin Pharmacol Ther, 1992;52:659-67
9 Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, et alPersad R..The procarcinogen hypothesis forbladdercancer:activities of individual drug metabolizing enzymes as risk factors[J].Pharmacogenetics, 1995;5:S97-102
10 Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ.Principles and clinical application of assessing alterations in renal elimination pathways[J].Clin Pharmacokinet, 2003;42:1193-211
11 Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE.Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways:absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol[J].BrJ Clin Pharmacol,2001;51:547-55
12 Zhang X, Lalezari JP, Badley AD, DorrA, Kolis SJ, Kinchelow T, et al.Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients[J].Clin Pharmacol Ther, 2004;75:558-68
13 ChristensenM, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al.The Karolinska cocktail forphenotyping of five human cytochrome P450 enzymes[J].Clin Pharmacol Ther, 2003;73:517-28
14 Zhu B, Ou-yang DS, Chen XP, Huang SL, Tan ZR.Assessment of cytochrome P450 activety by a five-drug cocktail approach[J].Clin pharmacol ther, 2001;70:455-61
15 Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M,Aherne Z, et al.Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail forCYPs 1A2, 3A4,Chin J Clin Pharmacol Ther2006 Nov;11(11)
16 2C9, 2D6 and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9 16 Sharma A, Pilote S, BelangerPM, ArsenaultM, Hamelin BA. A convenient five-drug cocktail forthe assessment of majordrug metabolizing enzymes:a pilot study[J]. and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9 16 Sharma A, Pilote S, BelangerPM, ArsenaultM, Hamelin BA. A convenient five-drug cocktail forthe assessment of majordrug metabolizing enzymes:a pilot study[J].BrJ Clin Pharmacol,2004;58:288-97
17 Yin OQ, Lam SS, Lo CM, Chow MS.Rapid determination of five probe drugs and theirmetabolites in human plasma and urine by liquid chromatography tandem mass spectrometry:application to cytochrome P450 phenotyping studies[J].Rapid Commun Mass Spectrom, 2004;18:2921-33
18 Jerdi MC, Daali Y, OestreicherMK, Cherkaoui S, DayerP.A simplified analytical method fora phenotyping cocktail of majorCYP450 biotransformation routes[J].J Pharm Biomed Anal,2004;35:1203-12
19 KrosserS, NeugebauerR, Dolgos H, Fluck M, Rost KL, KovarA.Investigation of sarizotan' s impact on the pharmacokinetics of probe drugs formajorcytochrome P450 isoenzymes:a combined cocktail trial[J].EurJ Clin Pharmaco, 2006;62:277-84
20 WexlerD, Courtney R, Richards W, Banfield C, Lim J, Laughlin M.Effect of posaconazole on cytochrome P450 enzymes:a randomized,open-label, two-way crossoverstudy[J].EurJ Pharm Sci, 2004;21:645-53
21 Scott RJ, PalmerJ, Lewis IA, Pleasance S.Determination of a' GW cocktail' of cytochrome P450 probe substrates and theirmetabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry[J].Rapid Commun Mass Spectrom, 1999;13:2305-19
22 TuckerGT, Houston JB, Huang SM.Optimizing drug development: strategies to assess drug metabolism transporterpotentialtoward a consensus[J].Clin Pharmacol Ther, 2001;70:103-14
23 Food and Drug Administration.FDA Guidance forIndustry:In vivo Drug Metabolism Drug Interaction Studies-Study Design,Data Analysis, and Recommendations forDosing and Labeling[ S].Rockville, MD:FDA, 2005
24 Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M,et alAherne Z..Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail forCYPs 1A2, 3A4,2C9, 2D6 and 2E1[J].BrJ Clin Pharmacol, 2003;57:162-9
25 Paolini M, Biagi GL, BauerC, Cantelli-Forti G.Cocktail strategy:complications and limitations[J].J Clin Pharmacol, 1993;33:1011-2
26 Frye RF,Matzke GR, Adedoyin A, PorterJA, Branch RA.Validation of the five-drug “Pittsburgh cocktail” approach forassessment of selective regulation of drug-metabolizing enzymes[J].Clin Pharmacol Ther, 1997;62:365-76

[1]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[2]	邵明坤, 刘蓉, 孙品, 关水, 廖炳灿, 李莎, 丛滔, 梁凯, 马辉, 孙长凯. 褪黑素人体网络机制及其临床应用[J]. 中国临床药理学与治疗学, 2022, 27(9): 1031-1040.
[3]	王金伙, 郭建荣. 阿芬太尼的临床药理特性及其麻醉应用进展[J]. 中国临床药理学与治疗学, 2021, 26(7): 824-829.
[4]	吴懿, 方芳, 陈瑛, 樊军卫. 供受体CYP3A5基因型对肝移植术后早期他克莫司谷浓度的影响作用及其临床意义[J]. 中国临床药理学与治疗学, 2021, 26(6): 631-639.
[5]	梁庆, 王晖. 氮酮与薄荷醇联用对5-氟尿嘧啶的促透作用[J]. 中国临床药理学与治疗学, 2020, 25(7): 734-739.
[6]	吴茂锋, 刘畅, 戴慧晖, 麦长凤, 黄丹丽, 缪经纬, 刘丽忠, 方翼. pazopanib血药浓度个体差异与细胞色素P450 3A4基因多态性的关系初探[J]. 中国临床药理学与治疗学, 2020, 25(12): 1376-1380.
[7]	王玉珏, 尚新悦, 姚国栋. 芫花酯甲的药理作用与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(10): 1188-1194.
[8]	魏兆明，江文胜，高艺，张娟娟. 脂肪间充质干细胞的生物学特性及潜在临床应用[J]. 中国临床药理学与治疗学, 2019, 24(1): 116-120.
[9]	彭秋菊，严华成，石磊. 细胞色素P450 SNP与冠心病易感性关系的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(4): 477-480.
[10]	肖鹏，梅家转，白桦，栗敏，刘桂举，李瑞君，沈杰. 细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 159-164.
[11]	张培玉，任静，职文倩，刘澄铭，郜娜. 和厚朴酚等五种中药有效成分对CYP酶活性的体外抑制作用[J]. 中国临床药理学与治疗学, 2017, 22(8): 922-926.
[12]	许丽华，徐肖阳，徐骏军，俞文英. 表面修饰白蛋白纳米粒在肿瘤靶向治疗中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(8): 948-954.
[13]	刘晶晶, 梁智, 罗详冲, 何功浩, 冯恩富, 徐贵丽. LC-MS/MS法同时测定大鼠血浆中4种CYP450探针药物浓度[J]. 中国临床药理学与治疗学, 2017, 22(2): 144-150.
[14]	刘晓萍，赖香茂，王海全，陈玉梅，张冬梅. 药物整合在慢性阻塞性肺疾病合并焦虑抑郁障碍患者中的应用价值[J]. 中国临床药理学与治疗学, 2016, 21(9): 1038-1041.
[15]	韦艺丹，许美娟，季晖. 花生四烯酸的ω-羟化代谢途径与心脑血管疾病[J]. 中国临床药理学与治疗学, 2016, 21(7): 826-833.